Universal Beteiligungs und Servicegesellschaft mbH Acquires New Shares in Evolus, Inc. (NASDAQ:EOLS)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Evolus, Inc. (NASDAQ:EOLS) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 12,544 shares of the company’s stock, valued at approximately $151,000.

Several other institutional investors have also modified their holdings of EOLS. Raymond James Financial Inc. purchased a new stake in shares of Evolus during the fourth quarter valued at $575,000. KLP Kapitalforvaltning AS acquired a new position in Evolus in the 4th quarter worth about $106,000. Geode Capital Management LLC increased its holdings in shares of Evolus by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 1,214,590 shares of the company’s stock valued at $13,412,000 after acquiring an additional 3,969 shares during the last quarter. ExodusPoint Capital Management LP acquired a new position in shares of Evolus during the 4th quarter valued at about $149,000. Finally, Wells Fargo & Company MN boosted its stake in Evolus by 41.6% during the 4th quarter. Wells Fargo & Company MN now owns 49,347 shares of the company’s stock valued at $545,000 after purchasing an additional 14,506 shares during the period. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Stock Performance

EOLS stock opened at $8.91 on Wednesday. The business’s 50-day moving average price is $9.44 and its two-hundred day moving average price is $11.26. The company has a current ratio of 2.34, a quick ratio of 2.16 and a debt-to-equity ratio of 22.00. The firm has a market cap of $574.52 million, a PE ratio of -10.01 and a beta of 1.12. Evolus, Inc. has a 1-year low of $8.65 and a 1-year high of $17.82.

Analyst Ratings Changes

EOLS has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research report on Thursday, April 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Evolus in a report on Thursday, May 8th. Finally, BTIG Research began coverage on Evolus in a research report on Thursday, April 17th. They set a “buy” rating and a $21.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Evolus has an average rating of “Buy” and an average price target of $23.75.

Insiders Place Their Bets

In other Evolus news, CFO Sandra Beaver sold 6,494 shares of Evolus stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $10.02, for a total transaction of $65,069.88. Following the transaction, the chief financial officer directly owned 167,089 shares in the company, valued at approximately $1,674,231.78. The trade was a 3.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Rui Avelar sold 3,385 shares of the business’s stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $9.87, for a total value of $33,409.95. Following the completion of the sale, the insider owned 359,082 shares in the company, valued at approximately $3,544,139.34. This trade represents a 0.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 153,571 shares of company stock valued at $1,537,090. Insiders own 6.10% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.